Back to top

Analyst Blog

Chugai Pharmaceutical Company, Limited – a subsidiary of Roche (RHHBY - Analyst Report) – announced that the subcutaneous injectable version of its rheumatoid arthritis (RA) drug Actemra (tocilizumab) has been approved by the Japanese health authorities. The subcutaneous version of the drug has been approved for treating RA patients who have not responded adequately to one or more existing medications for the disease.

We note that a phase III study, conducted in Japan, demonstrated that the subcutaneous version of Actemra was as effective as its intravenous formulation. Moreover, the safety profiles of both versions were comparable. The subcutaneous version of the RA drug is currently under review in the US and the EU.

We remind investors that the intravenous version of Actemra is available in Japan since Jun 2005. Subsequently, the drug was cleared for additional RA indications (including prevention of structural damage of joints), polyarticular-course juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis (sJIA).

We note that the intravenous version of the drug is available in the EU (brand name: RoActemra) since 2009 for treating adult RA patients who have either responded insufficiently to, or were intolerant to, previous medication with one or more disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) inhibitors.

Actemra was approved by the US Food and Drug Administration (FDA) in Jan 2010 for treating adults suffering from moderately to severely active RA who have responded inadequately to one or more TNF inhibitors. The indication was expanded in Oct 2012.

The intravenous version is currently approved in more than 100 countries including the US, EU, India, Brazil, Switzerland and Australia. The RA market is highly competitive. Actemra primarily faces competition from UCB’s Cimzia and AbbVie Inc.’s (ABBV - Analyst Report) Humira in the RA space.

Roche, a large cap pharma company, carries a Zacks Rank #4 (Sell), reflecting short-term pressure on the stock. Novo Nordisk (NVO - Analyst Report) appears to be favorably placed in the large cap pharma space, carrying a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%